证券代码：833230 证券简称：欧康医药 公告编号：2025-051 成都欧康医药股份有限公司 关于公司食品生产许可证变更的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 成都欧康医药股份有限公司（以下简称"公司"）于近日取得成都市市场监 督管理局颁发的《食品生产许可证》，同意公司《食品生产许可证》的变更申请。 本次变更主要涉及新增 1 个类别——饮料产品的生产，其他内容不变。具体情况 如下： 一、变更后的《食品生产许可证》基本情况 生产者名称：成都欧康医药股份有限公司 统一社会信用代码：91510100698888960C 法定代表人（负责人）：赵卓君 住所：邛崃市临邛工业园区创业路 15 号 生产地址：邛崃市临邛工业园区创业路 15 号 食品类别：饮料，食品添加剂，蛋制品 许可证编号：SC20151018350046 有效期至：2028 年 9 月 13 日 发证机关：成都市市场监督管理局 二、对公司的影响 本次变更《食品生产许可证》是在原有的"蛋制品、食品添加剂"两类生产 类别的基础上，新 ...

Investment Rating - The report indicates a positive outlook for the industry, particularly in sectors such as military, robotics, and new energy vehicles, driven by policy support and technological innovation [5][30]. Core Insights - The North Exchange A-shares saw a trading volume of 25.47 billion yuan on August 6, 2025, an increase of 5.49 billion yuan from the previous trading day, with the North Exchange 50 Index closing at 1459.51, up 1.58% [3][14]. - The report highlights that 198 out of 269 companies listed on the North Exchange experienced price increases, with notable gainers including Huami New Materials (30.0%) and Fuheng New Materials (16.0%) [25][28]. - The report emphasizes the ongoing structural opportunities in the market, supported by the release of policy dividends and the development of emerging technology industries [7]. Summary by Sections Market Review - On August 6, 2025, the North Exchange A-shares had a trading volume of 25.47 billion yuan, with the North Exchange 50 Index rising by 1.58% and the specialized index increasing by 2.15% [3][14]. - The report notes that the automotive, defense, construction materials, and basic chemicals sectors showed strong performance, with military and robotics themes gaining traction due to policy support and technological advancements [5][30]. Important News - The report mentions a government initiative aiming to complete the construction and renovation of 300,000 kilometers of rural roads by 2027, enhancing rural transportation infrastructure [30]. - It also highlights Shanghai's plan for the embodied intelligence industry, targeting a core industry scale of 50 billion yuan, focusing on technological innovation and market integration [32]. Key Company Announcements - Tonghui Electronics reported a half-year revenue of 100 million yuan, a year-on-year increase of 16.81%, with a net profit of 29 million yuan, up 55.4% [33]. - Other companies such as Chengdian Guangxin and Gebijia announced plans for share reductions by major shareholders [35][36].

Investment Rating - The report indicates a positive outlook for the industry, particularly in sectors such as defense, robotics, and automotive, driven by policy support and technological innovation [3][6][18]. Core Insights - The North Exchange A-share trading volume reached 25.47 billion yuan on August 6, 2025, an increase of 5.49 billion yuan from the previous trading day, with the North Exchange 50 Index closing at 1459.51, up 1.58% [6][15]. - The report highlights that 198 out of 269 companies listed on the North Exchange saw their stock prices rise, with significant gains in companies like Huami New Materials (30.0%) and Fuheng New Materials (16.0%) [15][17]. - The report emphasizes the ongoing support from the central bank and other departments for new industrialization policies, which bolster market confidence in the growth potential of North Exchange companies [3][18]. Summary by Sections Market Review - On August 6, 2025, the North Exchange A-share trading volume was 25.47 billion yuan, with the North Exchange 50 Index increasing by 1.58% and the PE_TTM at 68.36 times [6][13]. - The North Exchange specialized index closed at 2516.96, reflecting a 2.15% increase [6][13]. Stock Performance - Among the 269 companies, 198 experienced price increases, while 68 saw declines. The top five gainers included Huami New Materials (30.0%), Fuheng New Materials (16.0%), and Mingyang Technology (15.7%) [15][17]. - The top five decliners were Sanyuan Gene (-6.1%), Hengli Drill Tools (-5.6%), and Beiyikang (-3.7%) [15][17]. Important News - The Ministry of Transport, Ministry of Finance, and Ministry of Natural Resources aim to complete the renovation of 300,000 kilometers of rural roads by 2027, enhancing safety and service capabilities [18]. - Shanghai's embodied intelligence industry plan targets a core industry scale of 50 billion yuan, focusing on technological innovation and support for applications [19]. Company Announcements - Tonghui Electronics reported a 16.81% year-on-year increase in revenue to 100 million yuan, with a net profit growth of 55.4% [20]. - Shareholder announcements included planned reductions in holdings by major stakeholders in Chengdian Guangxin and Gebijia [22][23].

Core Insights - The report highlights that in 2024, the total salary for A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 708,000 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share raw material pharmaceutical sector is 608,400 yuan [2] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [2] - The top five highest-paid company secretaries have annual salaries of 1.9309 million yuan, 1.514 million yuan, 1.2 million yuan, 1.17 million yuan, and 1.1 million yuan respectively [2] Age and Education Distribution - Company secretaries aged between 30 and 50 constitute 60% of the market, while those over 50 account for 38%, and those aged 30 or below make up 2% [1] - More than half of the company secretaries hold a bachelor's degree, with 9% having an associate degree, 52% a bachelor's degree, and 39% a master's degree [1] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [2] - The top five companies with the most investor meetings conducted 520, 437, 325, 323, and 291 meetings respectively [3]

Core Insights - The report highlights that in 2024, the total salary for A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Over 21% of company secretaries earn more than 1 million yuan annually, indicating a significant portion of high earners in this role [1] Salary Distribution - The average annual salary for secretaries in the A-share pharmaceutical sector is 608,400 yuan [5] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [5] - The top five highest-paid secretaries have salaries ranging from 1.0832 million to 1.9309 million yuan, with varying years of service [7] Age and Education Demographics - The majority of company secretaries (60%) are aged between 30 and 50 years, while 38% are over 50 years, and only 2% are 30 years or younger [1] - More than half (52%) of the secretaries hold a bachelor's degree, with 39% holding a master's degree and 9% holding an associate degree [3] Investor Relations - There is a significant variance in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [9] - The five companies with the highest number of investor meetings range from 291 to 520 meetings per year, with their secretaries' salaries varying widely [9]

证券代码：833230 证券简称：欧康医药 公告编号：2025-050 成都欧康医药股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 成都欧康医药股份有限公司 2024 年年度权益分派方案已获 2025 年 5 月 16 日召开的股东会审议通过，本次实施分配方案距离股东会审议通过的时间未超过 两个月。 二、权益登记日与除权除息日 现将权益分派事宜公告如下： 本次权益分派基准日合并报表归属于母公司的未分配利润为 99,513,799.39 元，母公司未分配利润为 102,692,722.20 元，母公司资本公积为 214,423,218.58 元（其中股票发行溢价形成的资本公积为 213,083,780.09 元，其他资本公积为 1,339,438.49 元）。本次权益分派共计转增 23,180,191 股，派发现金红利 7,726,730.40 元。 一、权益分派方案 1、本公司 2024 年年度权益分派方案为： 以公司现有总股本 77,267,304 股为 ...

Group 1: Product Pricing and Market Strategy - The price of the company's Huai Mi series products decreased by over 15% year-on-year, while the price of the Zhi Shi series products increased by over 35% year-on-year [4] - Future price trends will depend on raw material harvests and market competition; prices will decrease with abundant raw materials and increase with shortages [4] - The company aims to optimize product structure and reduce costs through new projects to mitigate price volatility risks [4] Group 2: Competitive Landscape - The plant extraction industry is highly segmented, with core products including natural pigments, plant essential oils, and active pharmaceutical ingredients [5] - Barriers to entry for competitors include overcoming technical extraction challenges and obtaining market access certifications [5] Group 3: Market Demand and Growth Potential - The global antioxidant market is projected to grow at a CAGR of 7.2% from 2023 to 2030, with plant extracts accounting for over 40% of the market [6] - The functional food market in China is expected to exceed 1.5 trillion yuan by 2025, driven by rising health demands and consumer spending [7] - The company's vitamin P products are anticipated to see sustained demand growth due to these market trends [7] Group 4: Core Technology and Production Capabilities - Key technological barriers in production include efficient extraction processes, stable large-scale production, and in-depth R&D capabilities [8] - The company has over ten years of experience in high-purity extraction, achieving over 99.5% purity for its quercetin products [8] - Continuous production techniques have improved extraction efficiency by over three times compared to traditional methods [8] Group 5: Strategic Development Plans - The company's development strategy involves three steps: deep processing of vitamin P raw materials, R&D of consumer-end products, and establishing a technical application center [9][11] - The strategy also includes dual market expansion in domestic and international markets, focusing on both pharmaceutical and food sectors [9][11] - The company plans to maintain growth by leveraging technological innovation and expanding into emerging markets like Southeast Asia [12]

北京德恒（重庆）律师事务所 北京德恒（重庆）律师事务所 关于成都欧康医药股份有限公司 2024 年年度股东会的法律意见 北京德恒（重庆）律师事务所 关于成都欧康医药股份有限公司 关于成都欧康医药股份有限公司 2024 年年度股东会的 法律意见 2024 年年度股东会的 法律意见 德恒 15G20250012-01 号 致：成都欧康医药股份有限公司 北京德恒（重庆）律师事务所接受成都欧康医药股份有限公司（以下简称"公 司"）的委托，指派赵禹吉律师、张瑞雪律师（以下简称"本所律师"）出席公 司 2024 年年度股东会（以下简称"本次股东会"），并对本次股东会的合法性进 行见证并出具法律意见。 本法律意见根据《中华人民共和国公司法》(以下简称"《公司法》")、《中 华人民共和国证券法》（以下简称"《证券法》"）等有关法律、法规、规范性 文件及《成都欧康医药股份有限公司章程》（以下简称"《公司章程》"）的相 关规定而出具。 为出具本法律意见，本所律师审查了公司本次股东会的有关文件资料。本所 律师得到公司如下保证，即其已提供了本所律师认为作为出具本法律意见所必需 的材料，所提供的原始材料、副本、复印件等材料、口头证言均 ...

证券代码：833230 证券简称：欧康医药 公告编号：2025-047 成都欧康医药股份有限公司 2024 年年度股东会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 5 月 16 日 2.会议召开地点：四川省邛崃市临邛工业园区创业路 15 号公司 B 区技术中 心办公楼三楼第二会议室 3.会议召开方式：现场投票与网络投票相结合 4.会议召集人：公司董事会 5.会议主持人：董事长赵卓君 6.召开情况合法合规的说明： （二）会议出席情况 出席和授权出席本次股东会的股东共 11 人，持有表决权的股份总数 56,460,492 股，占公司有表决权股份总数的 73.0716%。 其中通过网络投票参与本次股东会的股东共 0 人，持有表决权的股份总数 0 股，占公司有表决权股份总数的 0%。 （三）公司董事、监事、高级管理人员出席或列席股东会情况 1.公司在任董事 8 人，出席 8 人； 2.公司在任监事 3 人，出席 3 人； ...

Group 1: Investor Relations Activity Overview - The investor relations activity was conducted on May 15, 2025, at Chengdu Oukang Pharmaceutical Co., Ltd. [3] - Attendees included representatives from Kaiyuan Securities, Huayuan Securities, Zhongrui Huyin, and Luxin Chuangtou [3] - Company representatives included Chairman Zhao Zhuojun and CFO Cao Yongqiang [3] Group 2: Impact of Industry Trends - The overall price decline in the vitamin industry has limited impact on the company's product pricing, which is primarily influenced by raw material supply and market demand [5] - The company specializes in flavonoid products, a niche within the vitamin sector, using raw materials like bitter orange and sophora flower [5] Group 3: Production Capacity and Utilization - The new plant's production lines for bitter orange are expected to achieve over 50% capacity utilization by the end of 2025 [6] - The production lines for sophora flower are also projected to reach 50% capacity utilization by year-end 2025, with a focus on fine management and market expansion [6] Group 4: Market Expansion and Partnerships - The company has established strong partnerships in Japan for its sophora flower and bitter orange products, focusing on the food additive and health product markets [7] - Ongoing efforts are being made to deepen cooperation with clients and expand market influence in Japan [7] Group 5: Facility Upgrades and Compliance - Upgrades to the Diosmin and Rutin production lines have been completed, meeting both domestic and international GMP standards [8] - The upgraded lines have passed domestic GMP compliance checks and are in the process of obtaining EuGMP certification [8] Group 6: Financial Projections - The company anticipates a 160% increase in depreciation expenses for 2025 compared to 2024 due to the completion of investment projects [9] - Strategies will be implemented to enhance sales revenue to offset increased depreciation costs [9] Group 7: Profitability and Market Trends - The company's gross margin has declined due to production challenges and increased costs in Q1 2025, but is expected to recover as production lines stabilize [11] - The market for quercetin is projected to grow significantly due to rising health awareness and demand for natural ingredients, particularly in health supplements and functional foods [12]